



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F.	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/143,828	143,828 08/31/1998		ANDERS BERKENSTAM	10806-65	4054
26161	7590	12/17/2003		EXAMINER	
FISH & RIC 225 FRANKI		SON PC	PAK, MICHAEL D		
BOSTON, M		0		ART UNIT	PAPER NUMBER
				1646	

DATE MAILED: 12/17/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

PTOL-326 (Re		ion Summary	Part of Paper No. 12102003				
3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)		nal Patent Application (PTO-152)				
	e of References Cited (PTO-892)	4) 🔲 Interview Sumn	nary (PTO-413) Paper No(s)				
13)∐ A sii 37 a) 14)∐ A re	cknowledgment is made of a claim for domestic nce a specific reference was included in the first CFR 1.78.  The translation of the foreign language pro- cknowledgment is made of a claim for domestic ference was included in the first sentence of the	priority under 35 U.S.C. § 1 t sentence of the specification visional application has been priority under 35 U.S.C. §§	19(e) (to a provisional application) n or in an Application Data Sheet. received. 120 and/or 121 since a specific				
a) <u>L</u>	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priori application from the International Bureau ee the attached detailed Office action for a list of	s have been received. I have been received in Applitive documents have been received (PCT Rule 17.2(a)).	ication No ceived in this National Stage				
	inder 35 U.S.C. §§ 119 and 120						
11)	Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Example 1.	on is required if the drawing(s) i	is objected to. See 37 CFR 1.121(d).				
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	The specification is objected to by the Examiner The drawing(s) filed onis/are: a\□ acce		the Eveminer				
	on Papers						
	Claim(s) are subject to restriction and/or	r election requirement.					
	Claim(s) <u>1, 2, 8, 9, 13-17, 51-58, 60</u> is/are rejected.  Claim(s) is/are objected to.						
	Claim(s) is/are allowed.  Claim(s) <u>1, 2, 8, 9, 13-17, 51-58, 60</u> is/are rejected.						
	a) Of the above claim(s) <u>59 and 61</u> is/are withdrawn from consideration.						
4)⊠	Claim(s) <u>1,2,8,9,13-17,51-58 and 60</u> is/are pen	nding in the application.					
Disposit	ion of Claims	•	,				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
		action is non-final.					
1)⊠	Responsive to communication(s) filed on 23 M	lay 2003.	,				
THE - External control	MAILING DATE OF THIS COMMUNICATION.  Pensions of time may be available under the provisions of 37 CFR 1.1  SIX (6) MONTHS from the mailing date of this communication.  Peperiod for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period ware to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply y within the statutory minimum of thirty (3 will apply and will expire SIX (6) MONTH	y be timely filed  30) days will be considered timely.  S from the mailing date of this communication.				
	or Reply						
	The MAILING DATE of this communication app	Michael Pak pears on the cover sheet with	the correspondence address				
	Office Action Summary	Examiner	Art Unit				
	Office Action Comments	09/143,828	BERKENSTAM ET AL.				
ł		Application No.	Applicant(s)				

Art Unit: 1646

#### **DETAILED ACTION**

#### Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 23 May 2003 has been entered.

### Response to Amendment

- 2. The amendment filed 8 January 2003 has been entered. Claims 1-2, 8-9, 13-17, 51-58, and 60 are examined.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. Applicant's arguments filed 8 January 2003, have been fully considered but they are not found persuasive.
- 5. Newly submitted claims 59 and 61 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:
  Claims 59 and 61 are drawn to group II.

Application/Control Number: 09/143,828

Art Unit: 1646

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 59 and 61 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

## Claim Rejections - 35 USC § 102

6. Claims 1-2, 8-9, 13-17, 51-58, and 60 are rejected under 35 U.S.C. 102(e) as being anticipated by Kausch et al.(A).

The reason for the rejection has been set forth previously.

Kausch et al. disclose the isolation of chromosome (column 5). The cell source are human cells (column 6, lines 5-15). Many chromosomes can be sorted at once (column 9, lines 29-43). Large amounts of pure chromosomes and DNA of the chromosomes is isolated (column 10, lines 22-25). Cells transfected with chromosomal DNA is disclosed (column 10, lines 22-25).

Claims encompass chromosomal DNA because the claims encompass polynucleotide sequence comprising the polynucleotide sequence encoding a polypeptide with SEQ ID NO:2 including the genomic DNA of SEQ ID NO:3. The isolated and purified chromosomes comprise the polynucleotide sequence encoding a polypeptide with SEQ ID NO:2. Chromosomal DNA inherently are operably linked to an expression control sequences. Chromosomal DNA inherently comprises heterologous sequence because it undergoes recombination.

Application/Control Number: 09/143,828

Art Unit: 1646

Page 4

Applicants argue that Kausch disclosure of human and mouse chromosomal DNA do not constitute disclosure of an isolated nucleic acid encourage the human polypeptide sequence of SEQ ID NO:2 or a fragment thereof containing the DBD and/or LBD. However, as discussed above the chromosomal DNA comprises the claimed nucleic acid especially the genomic DNA encompassing claims. The newly amended claims are still generic and encompasses the DNA of Kausch.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak, whose telephone number is (703) 305-7038. The examiner can normally be reached on Monday through Friday from 8:30 AM to 2:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Hichard D. PAU Michael Pak. Primary Patent Examiner Art Unit 1646 10 December 2003